Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019
June 21 2019 - 7:30AM
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage
pharmaceutical company focused on developing next generation
antibiotics (oral and IV) to treat infections caused by multi-drug
resistant pathogens in both community and hospital settings, today
announced it will make multiple presentations at ASM Microbe 2019,
being held in San Francisco from June 20-24, 2019
“The research we are presenting at ASM Microbe 2019 underscores
the need for better care in the diagnosis and treatment of uUTIs,”
said Michael Dunne, M.D., Chief Scientific Officer of Iterum
Therapeutics. “In both an open label clinical study as well as a
retrospective analysis of a leading U.S. health plan’s medical and
pharmacy claims database, it was concluded that patients with uUTIs
in the community treated with the most commonly prescribed
antibiotic for that infection, ciprofloxacin, have a significantly
greater rate of treatment failure when the organism is quinolone
resistant.”
Dr. Dunne will moderate Session S339 – Pipeline Drugs to Treat
Gram-negative Infections – and deliver a presentation titled
“Sulopenem: An oral Thiopenem Antibiotic for the Treatment of
Infections-associated Resistant Enterobacteriaceae” on June 23,
2019, at 1:30 p.m. PT in 306/307/308 South.
Iterum Therapeutics will also present three posters which will
be displayed in the Exhibit and Poster Hall on June 21, 2019, from
10:30 a.m. to 5 p.m. PT. Details are as follows.
Title: Failure of Empiric Treatment of
Uncomplicated Urinary Tract Infection (UTI) Associated with
Resistant PathogensSession: P403 – CIV01 –
Clinical Studies of Adult Infectious Diseases: Treatment of
Drug-resistant InfectionsPoster number:
CIV-140Presenter: Michael Dunne
Title: Clinical and Microbiologic Efficacy of
Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract
Infections in Adult WomenSession: P404 – CIV01 –
Clinical Studies of Adult Infectious Diseases: Urinary Tract
InfectionsPoster Number:
CIV-147Presenter: Michael Dunne
Title: Impact of Urine Analysis Methods in the
Diagnosis of Uncomplicated Urinary Tract
InfectionSession: P446 – CPHM03 – Diagnostic
Bacteriology: UTI TestingPoster Number:
CPHM-846Presenter: Stephen Aronin
The posters will be available after ASM Microbe 2019 under
“Publications” in the Our Science section of the company’s website
at www.iterumtx.com.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical
company dedicated to developing differentiated anti-infectives
aimed at combatting the global crisis of multi-drug resistant
pathogens to significantly improve the lives of people affected by
serious and life-threatening diseases around the world. Iterum
Therapeutics is advancing its first compound, sulopenem, a novel
penem anti-infective compound, in Phase 3 clinical development with
oral and IV formulations. Sulopenem has demonstrated potent in
vitro activity against a wide variety of gram-negative,
gram-positive and anaerobic bacteria resistant to other
antibiotics. Iterum Therapeutics has received Qualified Infectious
Disease Product (QIDP) and Fast Track designations for its oral and
IV formulations of sulopenem in seven indications. For more
information, please visit http://www.iterumtx.com.
Forward-looking Statements
This press release may contain forward-looking statements. These
forward-looking statements include, without limitation, statements
regarding the development, therapeutic and market potential of
sulopenem. In some cases, forward-looking statements can be
identified by words such as “may,” “believes,” “intends,” “seeks,”
“anticipates,” “plans,” “estimates,” “expects,” “should,”
“assumes,” “continues,” “could,” “will,” “future,” “potential” or
the negative of these or similar terms and phrases. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause Iterum Therapeutics’ actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Forward-looking statements include
all matters that are not historical facts. Actual future results
may be materially different from what is expected due to factors
largely outside Iterum Therapeutics’ control, including the
uncertainties inherent in the conduct of clinical trials, clinical
trial patient enrollment, availability and timing of data from
clinical trials, changes in regulatory requirements or decisions of
regulatory authorities, the actions of third-party clinical
research organizations, suppliers and manufacturers,
commercialization plans and timelines, if approved, and other
factors discussed under the caption “Risk Factors” in its most
recently filed Quarterly Report on Form 10-Q, and other documents
filed with the SEC from time to time. Forward-looking statements
represent Iterum Therapeutics’ beliefs and assumptions only as of
the date of this press release. Except as required by law, Iterum
Therapeutics assumes no obligation to update these forward-looking
statements publicly, or to update the reasons actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
Investor Contact:
Judy Matthews Chief Financial Officer 312-778-6073
IR@iterumtx.com
Media Contact:
Claire LaCagnina 6 Degrees
315-765-1462clacagnina@6degreespr.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Sep 2023 to Sep 2024